Dec 16 2014

Americord Funds Clinical Trial using Donor Stem Cells

Posted by admin

Americord Funds Clinical Trial Examining the Use of Donor Stem Cells in Patients with Previously Treated Cancers

Funds Will Support Research into Treating Patients Who Have Received Chemotherapy For Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

New York – December 16, 2014Americord Registry announced today that it has provided funding to the Masonic Cancer Center at the University of Minnesota. Funding will support research into the possible use of donor stem cells in patients with previously treated lymphoma, myeloma, or chronic lymphocytic leukemia. All three are cancers of the blood or bone marrow.

Researchers are interested in using donor stem cells to further treat patients who have previously received chemotherapy. The use of chemotherapy, such as cyclophosphamide and busulfan, helps stop the growth of cancer cells. In addition, chemo stops the patient’s immune system from rejecting the donor’s stem cells. The donated stem cells from bone marrow or umbilical cord blood may be able to replace the patient’s immune cells and help destroy any remaining cancer cells.

Americord’s donation of funds is part of the company’s Corporate Giving Program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

“Americord is committed to supporting the advancement of stem cell treatments and technologies,” said Americord CEO Martin Smithmyer. “We are excited about the research being done at the Masonic Cancer Center and the potential it has for future treatment options.”

The study at the Masonic Cancer Center began in February 2008 and is anticipated to be complete by January 2015. It is registered with in accordance with best practices and requirements of the U.S. Food and Drug Administration.

For more information about the clinical trial, visit:

< Back to Blog
Category: Press